Kwality Pharmaceuticals Limited

BSE: 539997 NSE: KPL
Kwality Pharmaceuticals Limited - pharma in Amritsar, Punjab, India. FY 2026 financials & compliance.
CIN L24232PB1983PLC005426 Incorporated 04 May 1983 ROC Chandigarh HQ Amritsar, Punjab, India
Active Listed - NSE: KPL · BSE: 539997 Public Limited Company pharma
Data last updated
Market Cap
₹3,754 Cr
KPL · NSE
Share Price
₹3,528.40
-2.48% today
Revenue
₹503 Cr
FY 2025-26 · +35.9% YoY
EBITDA
₹117 Cr
Margin 23.3%
Net Profit
₹67.45 Cr
FY 2025-26 · +69.4% YoY
P/E (TTM)
43.6x
P/B 10.8x
ROE
22.7%
ROCE 23.8%
Debt / Equity
0.41
Interest cover 11.2x

About Kwality Pharmaceuticals Limited

Data last updated:

Kwality Pharmaceuticals Limited is a public limited company based in Amritsar, Punjab, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 May 1983 and has been in existence for over 43 years.

The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L24232PB1983PLC005426. Its GSTIN is 03AAACK6458M1ZB (Punjab). The company holds 5 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 539997 and NSE: KPL.

The company has an authorised share capital of ₹16 Cr and a paid-up capital of ₹10.38 Cr. It was formerly known as Kwality Pharmaceuticals Private Limited. It is led by directors including Ramesh Kumar (Managing Director) and Ajay Kumar Arora (Whole-Time Director).

Its last annual general meeting (AGM) was held on 09 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Village Nagkalan Majitha Road, Amritsar, Punjab, India – 143601.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹503.08 Cr, a growth of 35.9% compared to the previous year. For the same year it recorded a net profit of ₹67.45 Cr (net margin 13.4%) and EBITDA of ₹117.42 Cr (EBITDA margin 23.3%). The net worth stands at ₹331.6 Cr (up 25.6% YoY). Total assets are valued at ₹467.75 Cr (up 24.7% YoY).

The company has about 536 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Kwality Pharmaceutical. As per MCA filings, the company has open charges of ₹208.18 Cr and satisfied charges of ₹25.45 Cr on record. Court records list 130 cases involving the company, including 62 filed by the company and 68 filed against it; 48 cases are pending. The company has 23 deals on record (22 market trades, 1 ipo); the latest was in January 2026. The company has 14 MSME Form 1 returns on record between 2019 and 2023, listing 2,361 overdue payments to 288 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kwalitypharma.com.

Company details

CIN L24232PB1983PLC005426
Registration Number 005426
Incorporation Date 04 May 1983
ROC Chandigarh
Listing Status Listed - Listed on NSE (KPL); Listed on BSE (539997)
Company Status Active
Date of Last AGM 09 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Kwality Pharmaceuticals has one previous CIN (Corporate Identification Number): U24232PB1983PLC005426. The current CIN is L24232PB1983PLC005426, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24232PB1983PLC005426Current
U24232PB1983PLC005426Previous
Key People
Ramesh Kumar Managing Director Ajay Kumar Arora Whole-Time Director Geeta Arora Whole-Time Director

Contact details

Kwality Pharmaceuticals Limited's registered office is in Amritsar, Punjab. Its website is kwalitypharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    kwalitypharma.com
  • Social Media
  • Registered Address
    Village Nagkalan Majitha Road, Amritsar, Punjab, India – 143601
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Kwality Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Kwality Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Kwality Pharmaceuticals operates one associated brand: Kwality Pharmaceutical. Each brand links to its own profile.

BrandDescriptionWebsite
Kwality Pharmaceutical
Developer and manufacturer of generic tablets, capsules, syrup, and injectableskwalitypharma.com

Business activity

The main business activity of Kwality Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Kwality Pharmaceuticals Limited, buy the company report.

Financials of Kwality Pharmaceuticals Limited

FY 2025-26 filings available

Kwality Pharmaceuticals Limited reported revenue of ₹503.08 Cr (up 35.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹503 Cr
+35.9% YoY
EBITDA
₹117 Cr
+46.0% YoY
Profit After Tax
₹67.45 Cr
+69.4% YoY
Net Worth
₹332 Cr
+25.6% YoY
Total Assets
₹468 Cr
+24.7% YoY
Total Debt
₹130 Cr
+16.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.1%+88.1%-
EBITDA11780.4059.2244.2017228.8614.22
EBITDA margin+23.3%+21.7%+19.3%+17.6%+37.6%+11.0%+10.2%
Profit before tax89.5054.1531.1025.5716221.2810.93
Net profit67.4539.8129.0931.5712015.178.25
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.8%+5.9%
EPS (₹)64.9038.4022.9318.67115.6414.608.02
Balance sheet
Total assets46837532129023511189.73
Net worth33226422420118161.1646.01
Total debt13011298.1290.2754.0141.2334.97
Cash & bank3.5914.765.947.3612.955.811.54
Net working capital28121216914412246.1342.74
Cash flow
Cash from operations17.0652.7242.9841.3860.6026.716.16
Cash from investing(34.91)(28.52)(26.40)(48.44)(62.93)(23.20)(17.80)
Cash from financing7.04(14.44)(17.40)0.995.660.7711.77
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.8%+46.2%+23.4%+39.2%---
Other income0.621.060.530.900.380.770.650.22
EBITDA41.0238.7629.1225.3524.1825.8917.5019.66
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.8%
Depreciation4.995.264.824.964.765.094.564.62
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6722.3518.4517.0419.0811.3912.55
Tax8.366.356.354.335.114.592.874.10
Net profit25.6325.3216.0014.1211.9314.498.528.45
EPS (₹)24.6924.3915.4213.6011.4913.958.218.15
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.4%+88.6%-
EBITDA11780.4559.5344.3417229.2614.13
EBITDA margin+23.3%+21.7%+19.4%+17.7%+37.7%+11.2%+10.2%
Profit before tax89.5054.2331.4625.7516221.7911.14
Net profit67.4539.8529.2931.6912015.428.35
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.9%+6.0%
EPS (₹)64.9038.4423.1118.76115.6914.868.13
Balance sheet
Total assets47137932429323711491.86
Net worth33326622620218362.5147.10
Total debt13011298.1290.2754.0141.2334.97
Cash & bank3.5414.295.046.0910.875.131.15
Net working capital28221317014512246.2542.38
Cash flow
Cash from operations17.0052.7743.3542.1959.2426.365.63
Cash from investing(34.91)(28.13)(26.40)(48.44)(62.98)(23.20)(17.13)
Cash from financing7.04(14.44)(17.40)0.995.660.8312.36
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.6%+46.2%+23.6%+39.2%---
Other income0.621.060.530.900.380.770.650.22
Total expenses12111894.3285.9687.2989.7866.9070.35
EBITDA41.0238.7429.1225.3524.1925.9017.5119.68
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.9%
Depreciation4.995.264.824.964.765.084.554.61
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6522.3518.4517.0519.1011.4112.58
Tax8.366.356.354.335.114.592.874.10

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.8%+46.2%+23.4%+39.2%---
Other income0.621.060.530.900.380.770.650.22
EBITDA41.0238.7629.1225.3524.1825.8917.5019.66
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.8%
Depreciation4.995.264.824.964.765.094.564.62
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6722.3518.4517.0419.0811.3912.55
Tax8.366.356.354.335.114.592.874.10
Net profit25.6325.3216.0014.1211.9314.498.528.45
EPS (₹)24.6924.3915.4213.6011.4913.958.218.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.1%+88.1%-
Other income2.861.921.832.943.511.593.66
Total expenses386290248207285233125
Employee cost51.1041.2630.4628.1618.8014.7010.92
EBITDA11780.4059.2244.2017228.8614.22
EBITDA margin+23.3%+21.7%+19.3%+17.6%+37.6%+11.0%+10.2%
Depreciation19.8118.2919.5614.9610.696.494.43
Interest10.979.8810.396.612.922.682.52
Profit before tax89.5054.1531.1025.5716221.2810.93
Tax22.1414.347.486.3041.626.382.71
Net profit67.4539.8129.0931.5712015.178.25
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.8%+5.9%
EPS (₹)64.9038.4022.9318.67115.6414.608.02
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.3810.3810.3810.3810.3810.3810.38
Reserves & surplus32125421419017150.7835.63
Shareholders' funds (net worth)33226422420118161.1646.01
Minority interest(1.67)(1.65)(1.63)(1.45)(1.35)(1.30)(1.04)
Secured loans13011298.1290.1553.3132.7229.42
Unsecured loans0.000.000.000.120.708.515.55
Total debt13011298.1290.2754.0141.2334.97
Total liabilities46837532129023511189.73
Assets
Gross block26123220717012882.2262.60
Net block15614613912091.7456.5342.69
Capital work in progress17.010.000.0014.2912.152.890.00
Investments0.000.000.000.000.005.173.99
Inventories78.2583.4778.3993.3753.3617.3622.42
Sundry debtors28015411471.6969.1335.7130.33
Cash & bank balances3.5914.765.947.3612.955.811.54
Loans & advances43.7831.2643.9741.8392.3742.5831.41
Total current assets40628424321422810185.70
Total current liabilities12472.1873.2970.0310655.3342.96
Net working capital28121216914412246.1342.74
Total assets46837532129023511189.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.022.263.079.135.811.541.40
Net cash from operating activities17.0652.7242.9841.3860.6026.716.16
Net cash from investing activities(34.91)(28.52)(26.40)(48.44)(62.93)(23.20)(17.80)
Net cash from financing activities7.04(14.44)(17.40)0.995.660.7711.77
Net change in cash(10.81)9.76(0.81)(6.07)3.334.270.14
Closing cash3.5914.765.947.3612.955.811.54
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+35.9%+20.5%+22.4%-45.0%+74.1%+88.1%-
EBITDA growth+46.0%+35.8%+34.0%-74.3%+494.8%+103.0%-
PBT growth+65.3%+74.1%+21.6%-84.2%+659.3%+94.7%+0.1%
Net income growth+69.4%+36.9%-7.9%-73.7%+691.0%+83.9%-
Revenue CAGR (3Y)+26.1%-6.7%+5.4%+21.7%+40.0%+24.0%+12.3%
EBITDA CAGR (3Y)+38.5%-22.3%+27.1%+45.9%+121.9%+35.2%+16.9%
Profitability & leverage
Net income margin+13.4%+10.8%+7.7%+7.7%+26.3%+5.7%+5.9%
Return on capital employed+23.8%+18.4%+15.9%+18.5%+94.9%+23.8%+17.3%
Return on net worth+22.7%+16.4%+13.7%+16.6%+99.7%+28.2%+20.1%
Debt / equity0.410.430.450.380.400.720.78
Long-term debt / equity0.070.070.110.130.160.270.22
Interest cover11.2415.9126.2022.611.8111.9825.74
Efficiency & per share
Fixed asset turnover2.051.701.641.694.373.662.56
Inventory turnover6.224.573.583.4212.9013.178.27
Debtors turnover2.322.763.303.578.707.934.05
EPS (₹)64.9038.4022.9318.67115.6414.608.02
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)318.80253.70215.31192.48173.8158.1643.57
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.6%+46.2%+23.6%+39.2%---
Other income0.621.060.530.900.380.770.650.22
Total expenses12111894.3285.9687.2989.7866.9070.35
EBITDA41.0238.7429.1225.3524.1925.9017.5119.68
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.9%
Depreciation4.995.264.824.964.765.084.554.61
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6522.3518.4517.0519.1011.4112.58
Tax8.366.356.354.335.114.592.874.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.4%+88.6%-
Other income2.861.921.832.943.511.593.92
Total expenses386290248207284232125
Employee cost51.1041.2430.4328.1018.7414.4810.68
EBITDA11780.4559.5344.3417229.2614.13
EBITDA margin+23.3%+21.7%+19.4%+17.7%+37.7%+11.2%+10.2%
Depreciation19.7918.2619.5114.9210.646.444.39
Interest10.979.8810.396.612.922.622.52
Profit before tax89.5054.2331.4625.7516221.7911.14
Tax22.1414.347.486.3041.626.382.71
Net profit67.4539.8529.2931.6912015.428.35
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.9%+6.0%
EPS (₹)64.9038.4423.1118.76115.6914.868.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.3810.3810.3810.3810.3810.3810.38
Reserves & surplus32325521619217252.1336.72
Shareholders' funds (net worth)33326622620218362.5147.10
Secured loans13011298.1290.1553.3132.7229.42
Unsecured loans0.000.000.000.120.708.515.55
Total debt13011298.1290.2754.0141.2334.97
Total liabilities47137932429323711491.86
Assets
Gross block25923020516912780.7961.18
Net block15414413812090.7755.5241.63
Capital work in progress17.010.000.0014.2912.152.890.00
Investments3.553.553.553.553.558.727.54
Inventories78.2583.4778.3993.3753.3617.3622.42
Sundry debtors28115611673.2970.7137.7830.35
Cash & bank balances3.5414.295.046.0910.875.131.15
Loans & advances43.7831.2643.9741.8392.3741.1731.28
Total current assets40728524321522710185.20
Total current liabilities12472.1873.2970.0210555.1942.82
Net working capital28221317014512246.2542.38
Total assets47137932429323711491.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.551.351.807.065.131.150.28
Net cash from operating activities17.0052.7743.3542.1959.2426.365.63
Net cash from investing activities(34.91)(28.13)(26.40)(48.44)(62.98)(23.20)(17.13)
Net cash from financing activities7.04(14.44)(17.40)0.995.660.8312.36
Net change in cash(10.87)10.20(0.45)(5.26)1.933.990.87
Closing cash3.5414.295.046.0910.875.131.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+35.9%+20.5%+22.4%-45.0%+74.4%+88.6%-
EBITDA growth+45.9%+35.1%+34.3%-74.2%+486.9%+107.1%-
PBT growth+65.0%+72.4%+22.2%-84.1%+642.0%+95.6%+2.2%
Net income growth+69.3%+36.1%-7.6%-73.6%+678.6%+84.7%-
Revenue CAGR (3Y)+26.1%-6.7%+5.5%+21.9%+40.3%+24.1%+13.3%
EBITDA CAGR (3Y)+38.3%-22.3%+26.7%+46.4%+124.1%+36.5%+18.2%
Profitability & leverage
Net income margin+13.4%+10.8%+7.8%+7.8%+26.3%+5.9%+6.1%
Return on capital employed+23.7%+18.3%+15.9%+18.5%+94.2%+24.0%+17.3%
Return on net worth+22.5%+16.3%+13.7%+16.6%+98.6%+28.6%+20.0%
Debt / equity0.410.430.440.380.390.710.75
Long-term debt / equity0.070.070.110.120.160.260.20
Interest cover11.2415.8925.9622.471.8111.4825.87
Efficiency & per share
Fixed asset turnover2.061.711.651.714.433.732.62
Inventory turnover6.224.573.583.4212.9013.158.24
Debtors turnover2.302.723.253.498.417.684.01
EPS (₹)64.9038.4423.1118.76115.6914.868.13
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)320.51255.43216.98193.93175.1759.4744.62

To see the full year-wise statements and ratios of Kwality Pharmaceuticals Limited, buy the company report.

Board of directors of Kwality Pharmaceuticals Limited

Kwality Pharmaceuticals has 10 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ajay Kumar Arora
Also directs: Bioburn Innovations Private Limited
Whole-Time Director01 Aug 199531 Years 2 MonthsCurrent
Geeta AroraWhole-Time Director01 Oct 201016 Years 0 MonthsCurrent
Anju AroraWhole-Time Director01 Oct 201016 Years 0 MonthsCurrent
Ramesh Kumar
Also directs: Kaler Biopharmachem Private Limited, Iair Infocom Private Limited, PHD Chamber of Commerce and Industry
Managing Director04 May 198343 Years 5 MonthsCurrent
Aditya AroraWhole-Time Director22 Oct 201511 Years 0 MonthsCurrent
Prashanth Vellanki
Also directs: Elsantis Biostrips India Private Limited, Prolead Financial Solutions Private Limited, Prolead Growth Solutions Private Limited and 5 more
Director16 Mar 20233 Years 7 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Auditor

Kwality Pharmaceuticals Limited is audited by ARORA AGGARWAL & CO. for the financial year 2023.

Auditor firmFinancial yearFirm registration number
ARORA AGGARWAL & CO.FY 2023021086N

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 54.90%, foreign institutional investors hold 3.10%, domestic institutional investors hold 0.60% and retail and other public shareholders hold 41.40%.

Promoters: 54.90%DII (Domestic Institutional): 0.60%FII (Foreign Institutional): 3.10%Retail & Others: 41.40%
Sep 2026
QUARTER
54.90% Promoters
0.60% DII (Domestic Institutional)
3.10% FII (Foreign Institutional)
41.40% Retail & Others
Promoter holding - history
Now 54.90% · Sep 2026High 54.90% · Jun 2026Low 54.80% · Dec 2025
53%53.8%54.5%55.3%56%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 54.80%Mar 2026: 54.80%Jun 2026: 54.90%Sep 2026: 54.90%54.90%54.80%54.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters54.90%54.90%54.80%54.80%
Public45.10%45.10%45.20%45.20%

Charges & borrowings

Open charges
₹208.18 Cr
Satisfied charges
₹25.45 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹144.51 Cr
Axis Bank Limited₹40.00 Cr
Others₹23.37 Cr
Director of Industries₹0.30 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
28 Jul 2026101350054Hdfc Bank Limited₹46 LakhOpen
29 May 2026101300371Hdfc Bank Limited₹23.12 LakhOpen
21 Nov 2025101229438Others₹1.3 CrOpen
15 Oct 2025101171798Hdfc Bank Limited₹10.09 LakhOpen
14 Oct 2025101171791Hdfc Bank Limited₹2.51 CrOpen

To see the full charge records of Kwality Pharmaceuticals Limited, buy the company report.

Total charge records: 42 View all charges

Deals & funding

Kwality Pharmaceuticals Limited has 23 deals on record (22 market trades, 1 ipo); the latest was in January 2026.

Total deals
23
Market trades
22
IPO
1

Deals on record (5 of 23)

WhenDealAmountParties
Jul 2023Market trade₹4.34 CrSeller: Aknm Suppliers Private Limited
Jul 2023Market trade₹4.43 CrBuyer: Bluepeak Consultancy LLP
Seller: Aknm Suppliers Private Limited
Jun 2023Market trade₹3.07 CrSeller: Aknm Suppliers Private Limited
Jun 2023Market trade₹4.66 CrSeller: Aknm Suppliers Private Limited
Jun 2023Market trade₹2.96 CrSeller: Aknm Suppliers Private Limited

To see the full deal history of Kwality Pharmaceuticals Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Kwality Pharmaceuticals Limited was last rated by Icra on 21 May 2021.

Rating agencyRated onRating
Icra21 May 2021

To see the full credit ratings and regulatory alerts of Kwality Pharmaceuticals Limited, buy the company report.

MSME payment delays

Kwality Pharmaceuticals Limited has 14 MSME Form 1 returns on record between 2019 and 2023, listing 2,361 overdue payments to 288 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 288)

SupplierAmount dueDue sinceReported on
Pinnacle Traxim Private Limited
Svam Toyal Packaging Industries Private Limited
an individual supplier
Ruskin Chemipharma
Sain Packaging Private Limited

To see the full MSME payment records of Kwality Pharmaceuticals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Kwality Pharmaceuticals Limited has a workforce of 536 employees on its EPFO records as of Feb 24, 2025, across 2 active EPFO establishments.

Employee count
536
Active EPFO establishments
2
Employee growth
5.3%

GST

Kwality Pharmaceuticals has 5 GST registrations: 3 active and 2 cancelled or inactive.

Total GSTINs
5
Active
3
Cancelled / inactive
2
GSTINStateStatusRegistered on
03AAACK6458M1ZBPunjabActive01 Jul 2017
02AAACK6458M2ZCHimachal PradeshActive01 Jul 2017
09AAACK6458M1ZZUttar PradeshActive19 Sep 2017

To see the full GST registrations and return filing status of Kwality Pharmaceuticals Limited, buy the company report.

Recent activity

Kwality Pharmaceuticals Limited has 25 board changes on record since 1983: 19 appointments and 6 cessations. The latest: Swanith Kapoor was appointed as Director on 02 Jun 2026.

Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.46 Cr with Charge ID 101350054 was registered on 28 Jul 2026.
Appointed
Swanith Kapoor was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.23 Cr with Charge ID 101300371 was registered on 29 May 2026.
Filing
Kwality Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Chandigarh.
Appointed
Bhavesh Mahajan was appointed as Director.
Appointed
Preetmohinder Singh Bedi was appointed as Director.
Charges
A charge with Others amounted to Rs. 1.30 Cr with Charge ID 101229438 was registered on 21 Nov 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.10 Cr with Charge ID 101171798 was registered on 15 Oct 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 2.51 Cr with Charge ID 101171791 was registered on 14 Oct 2025.
Charges
A charge with Others amounted to Rs. 0.27 Cr with Charge ID 101170470 was registered on 29 Sep 2025.
Charges
A charge with Axis Bank Limited of Rs. 40.00 Cr registered on 05 Nov 2016 with Charge ID 100069110 was modified on 26 Sep 2025.
AGM
Kwality Pharmaceuticals Limited last Annual general meeting of members was held on 09 Sep 2025 as per latest MCA records.

83 earlier events are in the company report.

News

Frequently asked questions

Kwality Pharmaceuticals is an active public limited company based in Amritsar, Punjab, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 May 1983 (43+ years old) and is registered under CIN L24232PB1983PLC005426. Listed on BSE: 539997 and NSE: KPL.

Kwality Pharmaceuticals reported revenue of ₹503.08 Cr for FY 2025-26 (up 35.9% YoY) based on consolidated financials.

Kwality Pharmaceuticals has 10 current directors:

The latest financial statements of Kwality Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 09 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Kwality Pharmaceuticals is 03AAACK6458M1ZB, registered in Punjab. The company has 5 GST registrations in all, of which 3 are active and 2 are cancelled or inactive. Other active GSTINs include 02AAACK6458M2ZC (Himachal Pradesh), 09AAACK6458M1ZZ (Uttar Pradesh).

The CIN (Corporate Identification Number) of Kwality Pharmaceuticals is L24232PB1983PLC005426. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Kwality Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 539997) and NSE (symbol: KPL).

Kwality Pharmaceuticals has 130 court cases on record: 62 filed by the company and 68 filed against it. 48 are pending. Most are in the district courts.

Kwality Pharmaceuticals was incorporated on 04 May 1983, making it 43+ years old. It is registered with the Registrar of Companies, Chandigarh.

Kwality Pharmaceuticals has 23 deals on record (22 market trades, 1 ipo); the latest was in January 2026.

Swanith Kapoor was appointed as Director on 02 Jun 2026. Bhavesh Mahajan was appointed as Director on 28 Jan 2026. Preetmohinder Singh Bedi was appointed as Director on 01 Jan 2026. Kwality Pharmaceuticals has 25 board changes on record in total.